Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state

International Journal of Urology

Volumn 12, Issue 10, 2005, Pages 899-905

  Oka, Hiroya ^a   Chatani, Yuji ^b   Kohno, Michiaki ^c   Kawakita, Mutsushi ^d   Ogawa, Osamu ^e  

^a Nara Health Insurance Hospital   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

Androgen independent; ERK (extracellular signal regulated protein kinase); Hormone refractory; MAP (mitogen activated protein) kinase; Prostate cancer

Indexed keywords

ANDROGEN; MITOGEN ACTIVATED PROTEIN KINASE; TESTOSTERONE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL CULTURE; DISEASE COURSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA; DISEASE PROGRESSION; ENZYME ACTIVATION; HUMANS; IMMUNOBLOTTING; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROSTATIC NEOPLASMS; RATS; SIGNAL TRANSDUCTION; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 28444445236     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01164.x     Document Type: Article

References (34)

1. Sturgill TW, Ray LB, Erikson E, Maller JE. Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 1988; 334: 715-18.
2. Kohno M. Diverse mitogenic agents induce rapid phosphorylation of a common set of cellular proteins at tyrosine in quiescent mammalian cell. J. Biol. Chem. 1985; 260: 1771-9.
3. Boulton TG, Nye SH, Robbins DJ et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663-75.
4. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 1993; 268: 14553-6.
5. Oka H, Chatani Y, Hoshino R et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995; 55: 4182-7.
6. Hoshino R, Chatani Y, Yamori T et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22.
7. Miyamoto M, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer, current status and future prospects. Prostate 2004; 61: 332-53.
8. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J. Urol. 2005; 173: 10-20.
9. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001; 1: 34-45.
10. Foster BA, Kaplan PJ, Greenberg NM. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev. 1999; 17: 317-24.
11. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin. Chem. 1998; 44: 705-23.
12. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin. Oncol. 2004; 31: 26-32.
13. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999; 59: 279-84.
14. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of p38 MAPK, Erk 1/2, and Jnk during the initiation and progression of prostate cancer. Prostate 2003; 55: 128-39.
15. Nemoto K, Vogt A, Oguri T, Lazo JS. Activation of the Raf-1/MEK/Erk kinase pathway by a novel cdc 25 inhibitor in human prostate cancer cells. Prostate 2004; 58: 95-102.
16. Unni E, Sun S, Nan B et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 2004; 64: 7156-68.
17. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/Mitogen-activated protein kinase signaling pathway promotos androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 2003; 63: 1081-9.
18. Matsumoto K, Sato B, Kitamura Y. Roles of androgen and its receptors in mouse mammary tumors. In: Leung BS (ed.). Hormonal Regulation of Mammary Tumors. Eden Press Inc., Montreal, 1982; 216-44.
19. Sato N, Watabe Y, Suzuki H, Shimazaki J. Progression of androgen-sensitive mouse tumor (shionogi carcinoma 115) to androgen-insensitive tumor after long-term removal of testosterone. Jpn J. Cancer Res. 1993; 84: 1300-8.
20. Ichikawa T, Akimoto S, Hayata I, Shimazaki J. Progression and selection in heterogeneous tumor composed of androgen-responsive shionogi carcinoma 115 and its autonomous subline (chiba subline 2). Cancer Res. 1989; 49: 367-71.
21. Class F-H-J, Van-Steenbrugge G-J. Expression of HLA-like structures on a permanent tumor line PC-93. Tissue Antigens 1983; 21: 227-32.
22. Romijn JC, Verkoelen CF, Schroeder FH. Determination of the growth rate of human prostatic cells in primary culture by a morphometric technique. Cell Biol. Int. Rep. 1984; 8: 363-71.
23. Romijn JC. Growth of tumor cells with different sensitivities for murine natural killer cells in young and adult athymic nude mice. Exp. Cell Biol. 1985; 53: 24-31.
24. Mobbs BG, Johnson IE. Basal and estrogen-stimulated hormone receptor profiles in four R3327 rat prostatic carcinoma sublines in relation to histopathology and androgen sensitivity. Cancer Res. 1988; 48: 3077-83.
25. Diamond DA, Barrack ER. The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines. J. Urol. 1984; 132: 821-7.
26. Suzuki F, Kashimoto M, Horikawa M. A replica plating method of cultured mammalian cells for somatic cell genetics. Exp. Cell Res. 1971; 68: 476-9.
27. Chatani Y, Tanaka E, Tobe K et al. Mitogen-induced tyrosine- phosphorylated 41- and 43-kDa proteins are family members of extracellular signal-regulated kinases/microtubule-associated protein 2 kinases. J. Biol Chem. 1992; 267: 9911-16.
28. Nakashima S, Chatani Y, Nakamura M, Miyoshi N, Kohno M, Nozawa Y. Tyrosine phosphorylation mitogen-activated protein kinases by thrombin in human platelets; possible involvement in late arachidonic acid release. Biochem. Biophys. Res. Commun. 1994; 198: 497-503.
29. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 1994; 54: 1566-73.
30. Yeh S, Lin H-K, Kang H-Y, Thin T-H, Lin M-F, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 1999; 96: 5458-63.
31. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathway. J. Urol. 2002; 277: 7076-85.
32. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J. Urol. 1999; 162: 1537-42.
33. Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch. 1998; 432: 407-13.
34. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinase in normal, hyperplastic, and carcinomatous human prostate. Hum. Pathol. 2002; 33: 299-306.